Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01148108 · ClinicalTrials.gov registry record · Phase 2
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
A Phase 2 study, sponsored by Telik.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01148108 is a Phase 2 study that has completed, run by Telik. The registered enrollment target is 14 participants.
The verdict
NCT01148108, a Phase 2 study, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma. The study will be conducted in two stages with 5-6 patients in each indication in Stage 1 and if responses are observed an additional 10 patients in Stage 2 in each group.
Interventions
- DRUG Canfosfamide HCl for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01148108
The ClinicalTrials.gov registry entry for NCT01148108 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Canfosfamide HCl for injection is the first listed.
NCT01148108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01148108 about?
NCT01148108 is a clinical study titled "Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma". This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma. The study will be conducted in two stages with 5-6 patients in each indication in Stage 1 and if responses are ob...
What is the current status of trial NCT01148108?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2010-06. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01148108?
The interventions under investigation include: Canfosfamide HCl for injection (DRUG).
Who is sponsoring clinical trial NCT01148108?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.